Combining Network Pharmacology and Neuroprotection: The Role of Mucuna pruriens in Huntington's Disease Management
DOI:
https://doi.org/10.64252/24fgt028Keywords:
Mucuna pruriens, Huntington's disease, neuroprotection, antioxidant, anti-inflammatory, L-DOPA, oxidative stress, Wistar rats, Network pharmacology, DPPH assay, ABTS assayAbstract
Objective: The present study investigated the phytochemical composition and neuroprotective potential of Mucuna pruriens extract in treating Huntington's disorder (HD) by focusing on their antioxidant and anti-inflammatory properties through both in vitro and in vivo rat models.
Material and methods:Wistar rats were divided into five groups, with each group consisting of eight animals, and given Mucuna pruriens extract at 100, 200, and 400 mg/kg orally for 14 days. Huntington’s disease was induced with 3-nitropropionic acid at 10 mg/kg/day intraperitoneally for two weeks. Network pharmacology identified target pathways, and antioxidant and anti-inflammatory effects were assessed with DPPH, ABTS, and mediator inhibition assays. Neuroprotection was evaluated through behavioural assessments and oxidative stress markers.
Results:Phytochemical and network pharmacology analyses of Mucuna pruriens extract identified high L-DOPA levels and multiple molecular targets relevant to Huntington's disease. The extract exhibited antioxidant and anti-inflammatory effects, reducing reactive oxygen species, lipid peroxidation, and inflammatory mediators. In a 3NP-induced HD model, Mucuna pruriens improved motor function, modulated oxidative stress, and preserved neuronal integrity, indicating its potential to mitigate HD progression.
Conclusion:Mucuna pruriens extract demonstrates significant neuroprotective effects against Huntington's disease through its antioxidant and anti-inflammatory properties. Future studies should explore its molecular mechanisms and clinical efficacy.
